Entereg Documents Offer Detailed Insight Into REMS Review Process
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.